U.S. patent application number 15/639223 was filed with the patent office on 2017-12-21 for multiple-component solid phases containing at least one active pharmaceutical ingredient.
The applicant listed for this patent is The Regents of the University of Michigan, University of South Florida. Invention is credited to Brian Moulton, Nair Rodriguez-Hornedo, Michael J. Zaworotko.
Application Number | 20170362182 15/639223 |
Document ID | / |
Family ID | 27789020 |
Filed Date | 2017-12-21 |
United States Patent
Application |
20170362182 |
Kind Code |
A1 |
Zaworotko; Michael J. ; et
al. |
December 21, 2017 |
MULTIPLE-COMPONENT SOLID PHASES CONTAINING AT LEAST ONE ACTIVE
PHARMACEUTICAL INGREDIENT
Abstract
The subject invention concerns a method for identifying
complementary chemical functionalities to form a desired
supramolecular synthon. The subject invention also pertains to
multiple-component phase compositions comprising one or more
pharmaceutical entities and methods for producing such
compositions.
Inventors: |
Zaworotko; Michael J.;
(Tampa, FL) ; Rodriguez-Hornedo; Nair; (Ann Arbor,
MI) ; Moulton; Brian; (Temple Terrace, FL) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
University of South Florida
The Regents of the University of Michigan |
Tampa
Ann Arbor |
FL
MI |
US
US |
|
|
Family ID: |
27789020 |
Appl. No.: |
15/639223 |
Filed: |
June 30, 2017 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10378956 |
Mar 3, 2003 |
|
|
|
15639223 |
|
|
|
|
60360768 |
Mar 1, 2002 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C07D 213/06 20130101;
C07C 61/135 20130101; C07C 233/25 20130101; C07C 51/43 20130101;
A61K 31/55 20130101; A61K 31/167 20130101; A61P 29/00 20180101;
C07C 53/08 20130101; C07C 63/307 20130101; C07C 53/02 20130101;
C07C 233/03 20130101; C07D 213/69 20130101; C07C 205/57 20130101;
C07D 275/06 20130101; C07D 233/74 20130101; C07C 53/124 20130101;
A61K 47/10 20130101; C07C 317/04 20130101; C07D 223/26 20130101;
A61P 25/08 20180101; A61K 9/1652 20130101; C07C 69/157 20130101;
C07D 213/82 20130101; C07D 213/79 20130101; A61K 31/616 20130101;
A61K 47/32 20130101; C07C 233/75 20130101; C07D 213/22 20130101;
C07C 57/30 20130101; A61K 31/4166 20130101; A61P 25/04 20180101;
C07C 47/544 20130101; C07C 57/58 20130101; A61K 31/192 20130101;
C07C 51/412 20130101; C07C 51/412 20130101; C07C 53/06 20130101;
C07C 51/412 20130101; C07C 53/10 20130101; C07C 51/412 20130101;
C07C 57/30 20130101; C07C 51/412 20130101; C07C 61/135 20130101;
C07C 51/43 20130101; C07C 57/30 20130101; C07C 51/43 20130101; C07C
53/06 20130101; C07C 51/43 20130101; C07C 61/135 20130101; C07C
51/43 20130101; C07C 53/10 20130101 |
International
Class: |
C07D 223/26 20060101
C07D223/26; A61K 9/16 20060101 A61K009/16; C07D 213/82 20060101
C07D213/82; C07D 213/79 20060101 C07D213/79; C07D 213/69 20060101
C07D213/69; C07D 213/22 20060101 C07D213/22; C07D 213/06 20060101
C07D213/06; C07C 317/04 20060101 C07C317/04; C07C 233/75 20060101
C07C233/75; C07C 233/25 20060101 C07C233/25; C07C 233/03 20060101
C07C233/03; C07C 205/57 20060101 C07C205/57; C07C 69/157 20060101
C07C069/157; C07C 63/307 20060101 C07C063/307; C07C 61/135 20060101
C07C061/135; C07C 57/58 20060101 C07C057/58; C07C 57/30 20060101
C07C057/30; C07C 53/124 20060101 C07C053/124; C07C 53/08 20060101
C07C053/08; C07C 53/02 20060101 C07C053/02; C07C 51/43 20060101
C07C051/43; C07C 51/41 20060101 C07C051/41; C07C 47/544 20060101
C07C047/544; A61K 47/32 20060101 A61K047/32; A61K 47/10 20060101
A61K047/10; A61K 31/616 20060101 A61K031/616; A61K 31/55 20060101
A61K031/55; A61K 31/4166 20060101 A61K031/4166; A61K 31/192
20060101 A61K031/192; A61K 31/167 20060101 A61K031/167; C07D 233/74
20060101 C07D233/74; C07D 275/06 20060101 C07D275/06 |
Claims
1. A multiple-component phase composition comprising a solid phase
that is sustained by intermolecular interactions between two or
more independent molecular entities, wherein at least one of said
two or more independent molecular entities is a pharmaceutical
molecule.
2. The multiple-component phase composition of claim 1, wherein
said multiple-component phase composition is a discrete
supramolecular entity or a polymeric structure.
3. (canceled)
4. The multiple-component phase composition of claim 1, wherein
said pharmaceutical molecule is sustained by a supramolecular
homosynthon when said pharmaceutical molecule is in its pure
phase.
5. The multiple-component phase composition of claim 1, wherein
said multiple-component phase composition has at least one physical
property or chemical property that is different from that of said
pharmaceutical when said pharmaceutical molecule is in its pure
phase, wherein said at least one physical or chemical property is
selected from the group consisting of chemical stability,
thermodynamic stability, solubility, dissolution, bioavailability,
crystal morphology, and hygroscopicity.
6-8. (canceled)
9. The multiple-component phase composition of claim 1, wherein
said pharmaceutical molecule is selected from the group consisting
of aspirin, acetaminophen, profen, phenytoin, and
carbamazepine.
10. The multiple-component phase composition of claim 1, wherein
said two or more independent molecular entities are selected from
the group consisting of: acetaminophen, 4,4'-bipyridine, and water;
phenytoin and pyridine; aspirin and 4,4'-bipyridine; ibuprofen and
4,4'-bipyridine; flurbiprofen and 4,4'-bipyridine; flurbiprofen,
trans-1,2-bis(4-pyridyl)ethylene; carbamazepine, p-phthalaldehyde;
carbamazepine and nicotinamide; carbamazepine and saccharin;
carbamazepine and 2,6-pyridinedicarboxylic acid; carbamazepine and
5-nitroisophthalic acid; carbamazepine and acetic acid;
carbamazepine and 1,3,5,7,-adamantanetetracarboxylic acid;
carbamazepine and benzoquinone; carbamazepine and butyric acid;
carbamazepine and dimethyl stilfoxide; carbamazepine and formamide;
carbamazepine and formic acid; and carbamazepine and trimesic
acid.
11. The multiple-component phase composition of claim 1, wherein
said intermolecular interactions are selected from the group
consisting of hydrogen bonding (weak and/or strong), dipole
interactions (induced and/or non-induced), stacking interactions,
hydrophobic interactions, and other inter-static interactions.
12. The multiple-component phase composition of claim 1, wherein
said intermolecular interactions are between complementary chemical
functionalities on said two or more independent molecular
entities.
13. The multiple-component phase composition of claim 1, wherein
said complementary chemical functionalities include at least one
chemical functionality selected from the group consisting of acids,
amides, aliphatic nitrogen bases, unsaturated aromatic nitrogen
bases, amines, alcohols, halogens, sulfones, nitro groups,
S-heterocycles, N-heterocycles, O-heterocycles, ethers thioethers,
thiols, esters, thioesters, thioketones, epoxides, acetonates,
nitrils, oximes, and organohalides.
14. The multiple-component phase composition of claim 12, wherein
said complementary chemical functionalities on said two or more
independent molecular entities are the same.
15. The multiple-component phase composition of claim 14, wherein
said complementary chemical functionalities are acids.
16. The multiple-component phase composition of claim 14, wherein
said complementary chemical functionalities are amides.
17. The multiple-component phase composition of claim 12, wherein
said complementary chemical functionalities on said two or more
independent molecular entities are not the same.
18. The multiple-component phase composition of claim 17, wherein
said complementary chemical functionalities on said two or more
independent molecular entities are selected from the group
consisting of acids and amides; pyridines and amides; and alcohols
and amines.
19-24. (canceled)
25. A method for identifying complementary chemical functionalities
in order to form a desired supramolecular synthon, said method
comprising: (a) evaluating the structure of an active
pharmaceutical ingredient; (b) determining whether the active
pharmaceutical ingredient contains chemical functionalities capable
of forming supramolecular synthons with itself; (c) identifying
from a plurality of chemical functionalities that are known to form
a supramolecular synthon at least one functionality that will form
a further supramolecular synthon to the supramolecular synthon
formed by the active pharmaceutical ingredient, wherein the
identified chemical functionality is not capable of disrupting
non-covalent bonding within the supramolecular synthon formed by
the supramolecular synthon formed by the active pharmaceutical
ingredient, and wherein the selected chemical functionality is
capable of forming a noncovalent bond to the supramolecular synthon
formed by the active pharmaceutical ingredient; and (d) identifying
co-crystal formers having chemical functionalities that are
complementary with the active pharmaceutical ingredient.
26. The method of claim 25, wherein said method further comprises
preparing a multiple-component solid phase composition, wherein the
multiple-component solid phase composition comprises the active
pharmaceutical ingredient and at least one of the identified
co-crystal formers.
27-28. (canceled)
29. A method for identifying complementary chemical functionalities
in order to form a desired supramolecular synthon, said method
comprising: (a) evaluating the structure of an active
pharmaceutical ingredient; (b) determining whether the active
pharmaceutical ingredient contains chemical functionalities capable
of forming supramolecular synthons with itself; (c) identifying
from a plurality of chemical functionalities that are known to form
supramolecular synthons at least one functionality that will form a
supramolecular synthon with the active pharmaceutical ingredient,
wherein the identified chemical functionality is capable of
disrupting non-covalent bonding within the supramolecular synthon
formed by the active pharmaceutical ingredient, and wherein the
selected chemical functionality is capable of forming a noncovalent
bond to a complementary chemical functionality on the active
pharmaceutical ingredient; and (d) identifying co-crystal formers
having chemical functionalities that are complementary with the
active pharmaceutical ingredient.
30. The method of claim 29, wherein said method further comprises
preparing a multiple-component solid phase composition, wherein the
multiple-component solid phase composition comprises the active
pharmaceutical ingredient and at least one of the identified
co-crystal formers.
31-32. (canceled)
33. A method for identifying complementary chemical functionalities
in order to form a desired supramolecular synthon, said method
comprising: (a) evaluating the structure of an active
pharmaceutical ingredient; (b) determining whether the active
pharmaceutical ingredient contains chemical functionalities capable
of forming supramolecular synthons with different molecules; (c)
identifying from a plurality of chemical functionalities that are
known to form supramolecular synthons at least one functionality
that will form a supramolecular synthon with the active
pharmaceutical ingredient, and wherein the selected chemical
functionality is capable of forming a noncovalent bond to a
complementary chemical functionality on the active pharmaceutical
ingredient; and (d) identifying co-crystal formers having chemical
functionalities that are complementary with the active
pharmaceutical ingredient.
34. The method of claim 33, wherein said method further comprises
preparing a multiple-component solid phase composition, wherein the
multiple-component solid phase composition comprises the active
pharmaceutical ingredient and at least one of the identified
co-crystal formers.
35-36. (canceled)
Description
CROSS-REFERENCE TO RELATED APPLICATION
[0001] The present application claims the benefit of priority of
U.S. Provisional Application Ser. No. 60/360,768, filed Mar. 1,
2002, which is hereby incorporated by reference herein in its
entirety, including any figures, tables, or drawings.
BACKGROUND OF THE INVENTION
[0002] The last decade has witnessed tremendous advances in the
understanding of, and the ability to manipulate, molecular and
supramolecular assemblies (Moulton, B. et al., Chem. Rev., 2001,
101:1629-1658). There are new paradigms concerning the design and
synthesis of a new generation of functional materials and
molecules. Such advances are a consequence of the fundamental
importance of intermolecular interactions, structure and
cooperativity in many aspects of molecular science, from
environmental science to molecular biology, to pharmacology, to
materials science. Thus, the prospects for control and manipulation
of materials at the molecular level, particularly in areas related
to non-covalent bonding and nanotechnology, are now truly
exceptional. However, whereas crystal structure determination has
been a tool used by scientists since the 1920's, crystal structure
prediction remains a largely unmet goal (Ball, P. Nature, 1996,
381:648-650; Gavezzotti, A. Acc. Chem. Res., 1994, 27:309-314).
Furthermore, the existence of more than one crystalline form of a
given molecular compound, typically in the form of polymorphs or
solvates, represents both a problem and an opportunity (Desiraju,
G. R. Science, 1997, 278:404-405; Bernstein, J. et al., Angew,
Chem. Int. Ed. Engl., 1999, 38:3441-3461). This is particularly
true for the pharmaceutical industry.
[0003] Crystal engineering (Schmidt, G. M. J. Pure Appl. Chem.,
1971, 27:647-678; Desiraju, G. R. Crystal Engineering: the Design
of Organic Solids, 1989, Elsevier: Amsterdam) is predicated on the
assumption that crystals are de facto examples of self-assembly,
i.e. crystals are comprised from a series of molecular recognition
events or supramolecular synthons (Desiraju, G. R. Angew. Chem.,
Int. Ed. Engl., 1995, 34:2311-2327). It also offers a more
realizable goal than crystal structure prediction since it relies
on design and allows for careful selection of substrates, i.e.
substrates that are predisposed to form predictable self-assembled
superstructures can be targeted for study. Furthermore, the
prototypal molecules used in crystal engineering contain
exofunctional molecular recognition sites and they can be
complementary with themselves (self-assembly) (Boucher, E. et al.,
J. Org. Chem., 1995, 60:1408-1412) or with other molecules (modular
self-assembly) (Zaworotko, M. J. Chem. Soc. Rev., 1994, 23:283-288;
Sharma, C. V. K. and M. J. Zaworotko Chem. Commun., 1996,
2655-2656). Coincidentally, most pharmaceutical molecules also
contain exterior molecular recognition sites and, although this
makes them susceptible to polymorphism and solvate formation, it
also makes them attractive candidates for crystal engineering
studies.
[0004] The ability of crystalline self-assemblies to be built from
a bottom-up approach (Feynman, R. Engineering and Science, 1960,
22-36) could provide an exceptional control of the design of new
phases at a molecular level. This contrasts with the current
state-of-the-art: "The number of forms known for a given compound
is proportional to the time and money spent in research on that
compound" (McCrone, W. C. Polymorphism in Physics and Chemistry of
the Organic Solid-State, pp. 726, Fox et al. Eds., Interscience:
New York, 1965). This statement summarizes the predicaments and
opportunities that one faces when dealing with a need to assert
control over the composition and structure of pharmaceutical
compounds in the solid state. Specifically, physical properties of
crystalline solids are critically dependent on the internal
arrangement of molecules or ions, making prediction of composition,
crystal structure and morphology from knowledge of molecular
structure a scientific challenge of the highest order. However,
crystal structure prediction and even prediction of composition
remains a largely unmet goal. Nonetheless, crystal engineering
offers the intriguing possibility of using molecular components for
their ability to impart functional characteristics (such as
solubility, dissolution rate and stability) for the development of
new delivery systems.
[0005] Undesirable physicochemical properties, physiological
barriers, or issues of toxicity often limit the therapeutic benefit
of drugs. This has motivated research in drug delivery systems for
poorly soluble, poorly absorbed and labile substances. Crystalline
self-assemblies represent a promising delivery modality for
improving drug solubility, dissolution rate, stability and
bioavailability. In addition, enhancement of drug activity can be
achieved by means of inclusion complexation or molecular
encapsulation. These systems offer various advantages over
amorphous polymeric delivery systems both from design and stability
perspectives. In this context, the existence of more than one
crystalline form of a given compound, typically in the form of
polymorphs or solvates, represents both a problem and an
opportunity. Several factors further complicate the situation. For
example, the Food and Drug Administration's (FDA's) strict purity
requirements effectively mean that a particular crystalline phase
of a drug must be selected and that its composition must be
established. This has typically meant that a consistent X-ray
powder diffraction (XPD) pattern is required (Federal Drug
Administration Fed. Regist., 1997, 62:62893-62894). The need to
ensure that processing produces both purity and ease of processing
is problematic because many drug molecules are prone to form
multiple phases, and crystal size and morphology can vary for a
given phase. The commercial and public image costs of not ensuring
that processing is reliable and reproducible is at best very high,
as demonstrated by the recent pull back and reformulation of NORVIR
by ABBOTT LABORATORIES).
[0006] That XPD patterns have been relied on for quality control is
convenient but is in many ways unfortunate since XPD is not as
foolproof as single crystal X-ray crystallography (e.g. similar
patterns can be obtained for different phases, composition is not
unambiguously determined), and XPD does not determine crystal
packing. Knowledge of crystal packing is important because it helps
explain the solubility and composition of a particular phase and
provides other valuable information. However, the materials
properties of pharmaceuticals and the existence of polymorphs are
generally investigated at the tail end of the drug development
process.
[0007] Accordingly, it would be advantageous to provide a wide
range of novel solid phases having properties, such as melting
point, solubility, dissolution rate, chemical stability,
thermodynamic stability, and/or bioavailability, which are
different from existing solid forms of the pharmaceutical molecule
upon which they are based.
BRIEF SUMMARY OF THE INVENTION
[0008] The subject invention relates to the application of the
concepts of crystal engineering towards the design of new
pharmaceutical phases that contain more than one molecular
component.
[0009] The subject invention concerns multiple-component solids
having at least one active pharmaceutical ingredient. Examples of
pharmaceutical molecules that may be utilized as active
pharmaceutical ingredients in the multiple-component solids of the
subject invention include, but are not limited to, aspirin, one or
more members of the profen series (e.g., ibuprofen and
flurbiprofen), carbamazepine, phenytoin, and acetaminophen.
Multiple-component solids, such as multiple-component crystals,
containing these pharmaceutical ingredients and complementary
molecules (hereafter referred to as "cocrystal formers") have been
characterized by various techniques and can exhibit physical and/or
chemical properties that are the same or different from the parent
pharmaceutical ingredient as a direct result of alternative
molecular recognition patterns. These novel crystalline assemblies
can afford improved drug solubility, dissolution rate, stability
and bioavailability.
[0010] The subject invention relates to the application of the
concepts of crystal engineering towards the design of new
pharmaceutical solid phases, such as multiple-component phases,
using cocrystal formers that are complementary in the sense of
supramolecular chemistry, i.e. they form supramolecular synthons
with pharmaceutical molecules or ions. The cocrystal formers can
be, but are not limited to, solvent molecules, other drug
molecules, GRAS compounds, or approved food additives.
Pharmaceutical molecules or ions are inherently predisposed for
such crystal engineering studies since they already contain
molecular recognition sites that bind selectively to biomolecules,
and they are prone to supramolecular self-assembly. Examples of the
groups commonly found in active pharmaceutical ingredients, and
which are capable of forming supramolecular synthons include, but
are not limited to, acids, amides, aliphatic nitrogen bases,
unsaturated aromatic nitrogen bases (e.g. pyridines, imidazoles),
amines, alcohols, halogens, sulfones, nitro groups, S-heterocycles,
N-heterocycles (saturated or unsaturated), and O-heterocycles.
Other examples include ethers, thioethers, thiols, esters,
thioesters, thioketones, epoxides, acetonates, nitrils, oximes, and
organohalides. Some of these groups can form supramolecular
synthons with identical groups in similar or different molecules
and are termed homosynthons, e.g. acids and amides. Other groups
can form supramolecular synthons with different groups and are
termed heterosynthons, e.g. acid/amide; pyridine/amide;
alcohol/amine. Heterosynthons are particularly suitable for
formation of multiple-component crystals whereas homosynthons can
sometimes form multiple-component crystals.
[0011] In one aspect, the subject invention concerns methods for
identifying complementary chemical functionalities to form a
desired supramolecular synthon, wherein the method comprises the
steps of evaluating the structure of an active pharmaceutical
ingredient (API), which can include determining its crystal
structure; determining whether the API contains chemical
functionalities capable of forming supramolecular synthons with
itself; identifying from a plurality of chemical functionalities
that are known to form a supramolecular synthon at least one
chemical functionality that will form a further supramolecular
synthon to the supramolecular synthon formed by the API, wherein
the identified chemical functionality is not capable of disrupting
non-covalent bonding within the supramolecular synthon formed by
the supramolecular synthon formed by the API, and wherein the
selected chemical functionality is capable of forming a noncovalent
bond to the supramolecular synthon formed by the API; and
identifying co-crystal formers having chemical functionalities that
are complementary with the API.
[0012] In another aspect, the subject invention concerns methods
for identifying complementary chemical functionalities to form a
desired supramolecular synthon, wherein the method comprises the
steps of evaluating the structure of an API, which can include
determining its crystal structure; determining whether the API
contains chemical functionalities capable of forming supramolecular
synthons with itself; identifying from a plurality of chemical
functionalities that are known to form supramolecular synthons at
least one functionality that will form a supramolecular synthon
with the API, wherein the identified chemical functionality is
capable of disrupting non-covalent bonding within the
supramolecular synthon formed by the API, and wherein the selected
chemical functionality is capable of forming a noncovalent bond to
a complementary chemical functionality on the API; and identifying
co-crystal formers having chemical functionalities that are
complementary with the API. Thus, according to this method, the
formation of homosynthons for the purpose of disrupting the
intermolecular interactions between pharmaceutical moieties can be
carried out.
[0013] In still another aspect, the subject invention concerns
methods for identifying complementary chemical functionalities to
form a desired supramolecular synthon, wherein the method comprises
the steps of evaluating the structure of an API, which can include
determining its crystal structure; determining whether the API
contains chemical functionalities capable of forming supramolecular
synthons with different molecules; identifying from a plurality of
chemical functionalities that are known to form supramolecular
synthons at least one functionality that will form a supramolecular
synthon with the API, and wherein the selected chemical
functionality is capable of forming a noncovalent bond to a
complementary chemical functionality on the API; and identifying
co-crystal formers having chemical functionalities that are
complementary with the active pharmaceutical ingredient.
[0014] As indicated above, certain aspects of the subject invention
can involve selecting a chemical functionality that is capable of
disrupting the noncovalent bonding between identical
functionalities (homosynthon) and form a non-covalent bond between
different, yet complementary, functionalities (heterosynthon);
selecting a plurality of molecular entities that comprise the
complementary functionality (preferably GRAS compounds or approved
food additives); identifying additional chemical features on the
molecular entities that will not interfere with the formation of
the desired supramolecular synthon and that will impart the desired
physical properties to the target phase; and, optionally, preparing
a new solid phase that is composed of the pharmaceutical moiety and
the complementary molecular entity (such as a multiple-component
phase or two component phase) by crystallization techniques
comprising reactions in solvent, and/or solventless reactions, that
afford crystalline materials. Optionally, the methods can further
include at least one of the subsequent steps of determining the
structure of the new solid phase formed; and analyzing the physical
properties of the new solid phase.
[0015] The subject invention further concerns new solid phases
identified or produced using the methods identified herein, The
subject invention further pertains to a multiple-component phase
composition comprising a solid material (phase) that is sustained
by intermolecular interactions between two or more independent
molecular entities, in any stoichiometric ratio, wherein at least
one of the independent molecular entities is a pharmaceutical
entity. The multiple-component phase composition can be, for
example, a discrete supramolecular entity or a polymeric
structure.
BRIEF DESCRIPTION OF THE DRAWINGS
[0016] FIG. 1 shows the chemical structure of ibuprofen. The
external functionalities are an isopropyl group (encircled on the
left, in cyan) and a carboxylic acid (encircled on the right, in
magenta).
[0017] FIG. 2 shows a scheme with the synthon of pure ibuprofen on
the left and the supramolecular entity containing the synthon on
the right, demonstrating that pure phases of ibuprofen are
sustained by carboxylic acid-carboxylic acid interactions. The
standard chemical color correlation appears in all the figures
where color is utilized (e.g., red=oxygen; white=oxygen; dark
blue=nitrogen; light blue=fluorene; yellow=sulfur).
[0018] FIG. 3 shows a scheme wherein the carboxylic acid-carboxylic
acid interactions of ibuprofen are disrupted by co-crystallization
with an aromatic amine. Specifically, by using diamines, 2:1
multiple-component phases are produced.
[0019] FIGS. 4A-4B show an acetaminophen 1-D polymeric chain and an
acetaminophen/4,4'-bipyridine/water crystal, respectively. Reported
forms are monoclinic (P2.sub.l/n) (Haisa, M. et al., Acta
Crystallogr., Sect B, 1974, 30:2510) and orthorhombic (Pbca)
(Haisa, M. et al., Acta Crystallogr., Sect B, 1976, 32:1283)
polymorphs. The monoclinic polymorph forms pleated sheets with all
hydrogen bonding donors and acceptors interacting. The orthorhombic
polymorph forms form 1-D polymeric chains with all donors and
acceptors interacting.
[0020] FIGS. 5A-5B show pure phenytoin and a phenytoin/pyridone
co-crystal, respectively. Phenytoin has one known pure form
(Carmerman, A. et al., Acta Crystallogr., Sect B, 1971, 27:2207).
The crystal structure reveals a two dimensional polymeric network
formed by hydrogen bonds between both the carbonyl and 2.degree.
amine.
[0021] FIGS. 6A-6D show supramolecular entities containing synthons
and corresponding crystal structures of pure aspirin and
aspirin/4,4'-bipyridine. FIGS. 3A and 3B show the supramolecular
entity containing the synthon of pure aspirin and corresponding
crystal structure, respectively. FIGS. 6C and 6D show the
supramolecular entity containing the synthon and corresponding
co-crystal of aspirin/4,4'-bipyridine, respectively. The pure phase
(Chiari, G. et al., Acta Crystallogr., Sect B, 1981, 37:1623) of
acetylsalicylic acid, has centrosymmetric carboxylic acid
homodimers and crystallizes in the space group P2.sub.l/c, packing
in 2D polymeric sheets with hydrophobic planes.
[0022] FIGS. 7A-7D show supramolecular entities containing synthons
and corresponding crystal structures of pure ibuprofen
[2-(4-isobutylphenyl)propionic acid] and ibuprofen/4,4'-bipyridine.
FIGS. 7A and 7B show the supramolecular entity containing the
synthon of pure ibuprofen and corresponding crystal structure,
respectively. FIGS. 7C and 7D show the supramolecular entity
containing the synthon of ibuprofen/4,4'-bipyridine and
corresponding co-crystal, respectively. The reported crystal
structures of ibuprofen are racemic (McConnell, J. F. Cryst.
Strucut. Commun., 1974, 3:73) and S (+) forms (Freer, A. A. et al.,
Acta Crystallogr., Sect C (Cr. Str. Comm), 1993, 49:1378). Both
contain hydrogen bonded carboxylic acid homodimers. Racemic dimers
have centers of inversion across the dimer, which crystallize in
the space group P2.sub.l/c. The S (+) form contains asymmetric
dimers, which crystallize in the space group P2.sub.l. Both
crystals pack in 2-D polymeric sheets sustained by .pi.-.pi.
stacking and hydrophobic in-layer interactions.
[0023] FIGS. 8A-8D show supramolecular entities containing synthons
and corresponding crystal structures of pure flurbiprofen
[2-(2-fluror-4-biphenyl)propionic acid] and
flurbiprofen/4,4'-bipyridine. FIGS. 8A and 8B show the
supramolecular entity containing the synthon of pure flurbiprofen
and corresponding crystal structure, respectively. FIGS. 5C and 5D
show the supramolecular synthon of flurbiprofen/4,4'-bipyridine and
corresponding co-crystal, respectively. Flurbiprofen has one
reported pure form (Flippen, J. L. et al., Acta Crystallogr., Sect.
B, 1975, 31:926) and contain hydrogen bonded carboxylic acid
homodimers with a center of inversion and crystallizes in the P-1
space group. 2-D polymeric sheets are formed through .pi.-.pi. and
hydrophobic interactions from the phenyl rings.
[0024] FIGS. 9A and 9B show the supramolecular entity containing
the synthon of flurbiprofen/trans-1,2-bis(4-pyridyl)ethylene and
the corresponding crystal structure, respectively.
[0025] FIGS. 10A and 10B show the crystal structures of pure
carbamazepine and carbamazepine/p-phthalaldehyde, respectively.
Carbamazepine [5H-Dibenz(b,f)azepine-5-carboxamide] (CBZ) has been
shown to exist in at least three anhydrous forms and two solvated
forms (a dihydrate and an acetonate) (Himes, V. L. et al., Acta
Crystallogr., 1981, 37:2242-2245; Lowes, M. M. J. et al., J. Pharm.
Sci., 1987, 76:744-752; Reck., G. et al., Cryst. Res. Technol.,
1986, 21:1463-1468). The primary intermolecular interaction in
these crystal forms is the dimer formed between the carboxamide
moieties of each CBZ molecule forming centrosymmetric dimers. The
anhydrous polymorphs are monoclinic, trigonal, and triclinic. The
polymorphs are enantiotropically related with the monoclinic form
being the most thermodynamically stable at room temperature.
[0026] FIG. 11 shows the crystal structure of
carbamazepine/nicotinamide (vitamin B3).
[0027] FIG. 12 shows the crystal structure of
carbamazepine/saccharin, engineered using the
carbamazepine/nicotinamide co-crystal as a model.
[0028] FIGS. 13A-13C show the chemical structures of ibuprofen,
flurbiprofen, and aspirin, respectively.
[0029] FIGS. 14A and 14B show the crystal structures of
carbamazepine and carbamazepine/2,6-pyridinedicarboxylic acid,
respectively.
[0030] FIGS. 15A and 15B show the crystal structures of
carbamazepine and carbamazepine/5-nitroisophthalic acid,
respectively.
[0031] FIGS. 16A and 16B show the crystal structures of
carbamazepine and carbamazepine/acetic acid.
[0032] FIGS. 17A and 17B show the crystal structure of
carbamazepine and carbamazepine/adamantanetetracarboxylic acid.
[0033] FIGS. 18A and 18B show the crystal structure of
carbamazepine and carbamazepine/benzoquinone.
[0034] FIGS. 19A and 19B show the crystal structure of
carbamazepine and carbamazepine/butyric acid.
[0035] FIGS. 20A and 20B show the crystal structure of
carbamazepine and carbamazepine/DMSO.
[0036] FIGS. 21A and 21B show the crystal structure of
carbamazepine and carbamazepine/formamide.
[0037] FIGS. 22A and 22B show the crystal structure of
carbamazepine and carbamazepine/formic acid.
[0038] FIGS. 23A and 23B show the crystal structure of
carbamazepine and carbamazepine/trimesic acid.
[0039] FIG. 24 shows an exemplified scheme for preparing
multiple-component phase compositions of the subject invention.
DETAILED DISCLOSURE OF THE INVENTION
[0040] The subject invention relates to the application of the
concepts of crystal engineering towards the design of new
multiple-component solid phases, such as multiple-component
crystals, having at least one active pharmaceutical component.
Examples of multiple-component crystals of the subject invention
include, but are not limited to,
acetominaphen/4,4'-bipyridine/water, phenytoin/pyridone,
aspirin/4,4'-bipyridine, ibuprofen/4,4'-bipyridine,
flurbiprofen/4,4'-bipyridine, flurbiprofen/trans-1,2-bis(4-pyridyl)
ethylene, carbamazepine/p-phthalaldehyde,
carbamazepine/nicotinamide (GRAs), carbamazepine/saccharin (GRAs),
carbamazepine/2,6-pyridinedicarboxylic acid,
carbamazepine/5-nitroisophthalic acid, carbamazepine/acetic acid,
carbamazepine/1,3,5,7-adamantanetetracarboxylic acid,
carbamazepine/benzoquinone, carbamazepine/butyric acid,
carbamazepine/dimethyl sulfoxide (DMSO), carbamazepine/formamide,
carbamazepine/formic acid, and carbamazepine/trimesic acid, which
have been characterized by various techniques and exhibit physical
properties different from the parent pharmaceutical ingredient as a
direct result of hydrogen bonding interaction. These crystalline
assemblies can afford improved drug solubility, dissolution rate,
stability and bioavailability, for example.
[0041] In one aspect, the subject invention concerns methods for
identifying complementary chemical functionalities to form a
desired supramolecular synthon, wherein the method comprises the
steps of evaluating the structure of an active pharmaceutical
ingredient (API), which can include determining its crystal
structure; determining whether the API contains chemical
functionalities capable of forming supramolecular synthons with
itself; identifying from a plurality of chemical functionalities
that are known to form a supramolecular synthon at least one
chemical functionality that will form a further supramolecular
synthon to the supramolecular synthon formed by the API, wherein
the identified chemical functionality is not capable of disrupting
non-covalent bonding within the supramolecular synthon formed by
the supramolecular synthon formed by the API, and wherein the
selected chemical functionality is capable of forming a noncovalent
bond to the supramolecular synthon formed by the API; and
identifying co-crystal formers having chemical functionalities that
are complementary with the API.
[0042] In another aspect, the subject invention concerns methods
for identifying complementary chemical functionalities to form a
desired supramolecular synthon, wherein the method comprises the
steps of evaluating the structure of an API, which can include
determining its crystal structure; determining whether the API
contains chemical functionalities capable of forming supramolecular
synthons with itself; identifying from a plurality of chemical
functionalities that are known to form supramolecular synthons at
least one functionality that will form a supramolecular synthon
with the API, wherein the identified chemical functionality is
capable of disrupting non-covalent bonding within the
supramolecular synthon formed by the API, and wherein the selected
chemical functionality is capable of forming a noncovalent bond to
a complementary chemical functionality on the API; and identifying
co-crystal formers having chemical functionalities that are
complementary with the API. Thus, according to this method, the
formation of homosynthons for the purpose of disrupting the
intermolecular interactions between pharmaceutical moieties can be
carried out.
[0043] In still another aspect, the subject invention concerns
methods for identifying complementary chemical functionalities to
form a desired supramolecular synthon, wherein the method comprises
the steps of evaluating the structure of an API, which can include
determining its crystal structure; determining whether the API
contains chemical functionalities capable of forming supramolecular
synthons with different molecules; identifying from a plurality of
chemical functionalities that are known to form supramolecular
synthons at least one functionality that will form a supramolecular
synthon with the API, and wherein the selected chemical
functionality is capable of forming a noncovalent bond to a
complementary chemical functionality on the API; and identifying
co-crystal formers having chemical functionalities that are
complementary with the active pharmaceutical ingredient.
[0044] In each of the three aspects of the methods described above,
the methods can further comprise preparing a multiple-component
solid phase composition composed of the API and at least one of the
identified co-crystal formers. The identified co-crystal former can
be, for example, a different API, a GRAS compound, a food additive,
a low toxicity organic, or a metal-organic complex. Various methods
can be utilized for preparing the multiple-component solid phase
composition, such as crystallization from solution, cooling the
melt, sublimation and grinding, In addition, the methods of the
subject invention can further comprise either or both of the
following steps: determining the structure of the new
multiple-component solid phase composition, and analyzing the
physical and/or chemical properties of the new multiple-component
solid phase composition.
[0045] The subject invention further concerns new solid phases
identified or produced using the methods identified herein. The
subject invention further pertains to a multiple-component phase
composition comprising a solid material (phase) that is sustained
by intermolecular interactions between two or more independent
molecular entities, in any stoichiometric ratio, wherein at least
one of the independent molecular entities is a pharmaceutical
entity. The multiple-component phase composition of the subject
invention can be, for example, a discrete supramolecular entity or
a polymeric structure. The multiple-component phase compositions of
the subject invention can have properties, such as melting point,
solubility, dissolution rate, stability, and/or bioavailability,
which are different from the pharmaceutical compound, or compounds,
upon which they are based.
[0046] By way of example, the external functionalities of ibuprofen
are an isopropyl group and a carboxylic acid, as shown in FIG.
1.
[0047] Using the methods of the subject invention, it has been
determined that this interaction can be disrupted by
co-crystallization with an aromatic amine, as shown in FIG. 2.
Specifically, by using diamines, 2:1 multiple-component phases of
ibuprofen have been prepared, as shown in FIG. 3, as well as other
phases exemplified herein. Therefore, the methods of the subject
invention can be used to identify complementary chemical
functionalities and produce multiple-component phase compositions
for a variety of pharmaceuticals, including those pharmaceutical
compounds with structures very different those of ibuprofen,
flurbiprofen, and aspirin, which are shown in FIGS. 13A-13C,
respectively.
[0048] As used herein, the term "multiple-component phase" refers
to any solid material (phase) that is sustained by intermolecular
interactions between at least two independent molecular entities,
in any stoichiometric ratio, wherein at least one of the
independent molecular entities is a pharmaceutical entity. Examples
of intermolecular interactions include, but are not limited to one
or more of the following: hydrogen bonding (weak and/or strong),
dipole interactions (induced and/or non-induced), stacking
interactions, hydrophobic interactions, and other inter-static
interactions. Each independent molecular entity can be a discrete
supramolecular entity or polymeric structure, for example.
Preferably, one or more of the independent molecular entities
comprises a molecule of a "GRAS" compound, that is, a compound
"Generally Regarded as Safe by the Food and Drug Administration
(FDA)". More preferably, the GRAS compound is a non-pharmaceutical
entity.
[0049] The tennis "pharmaceutical entity", "pharmaceutical moiety",
"pharmaceutical component", "pharmaceutical molecule", and "active
pharmaceutical ingredient (API)", and grammatical variations
thereof, are used interchangeably herein to refer to any
biologically active moiety having a therapeutic effect on a human
or animal suffering from a given pathological condition, when
administered in a given concentration. Therefore, pharmaceutical
entities useful as the active pharmaceutical ingredients in the
multiple phase solids of the subject invention can be administered
to a human or animal, which may or may not be suffering from a
pathological condition, and the pharmaceutical entity can have a
prophylactic effect, a palliative effect, and/or be a curative
intervention. As used herein, these pharmaceutical entities are
intended to include pharmaceutically acceptable salts of a given
pharmaceutical entity that retain all or a portion of their
pharmaceutical activity. Pharmaceutical molecules or ions are
inherently predisposed for such crystal engineering studies since
they already contain molecular recognition sites that bind
selectively to biomolecules, and they are prone to supramolecular
self-assembly, Examples of the groups commonly found in active
pharmaceutical ingredients, and which are capable of forming
supramolecular synthons include, but are not limited to, acids,
amides, aliphatic nitrogen bases, unsaturated aromatic nitrogen
bases (e.g. pyridines, imidazoles), amines, alcohols, halogens,
sulfones, nitro groups, S-heterocycles, N-heterocycles (saturated
or unsaturated), and O-heterocycles. Other examples include ethers,
thioethers, thiols, esters, thioesters, thioketones, epoxides,
acetonates, nitrils, oximes, and organohalides. Other examples
include ethers, thioethers, thiols, esters, thioesters,
thioketones, epoxides, acetonates, nitrils, oximes, and
organohalides. Some of these groups can form supramolecular
synthons with identical groups in similar or different molecules
and are termed homosynthons, e.g., acids and amides. Other groups
can form supramolecular synthons with different groups and are
termed heterosynthons, e.g., acid/amide; pyridine/amide;
alcohol/amine. Heterosynthons are particularly suitable for
formation of multiple component crystals whereas homosynthons can
sometimes form multiple-component crystals.
[0050] As used herein, the term "supramolecular synthon" refers to
the sum of the components of a multi-component non-covalent
interaction, wherein the non-covalent interaction contributes to
the formation of a discrete supramolecular entity or polymeric
structure, wherein each component is a chemical functionality. A
supramolecular synthon can be a dimer, trimer, or n-mer, for
example.
[0051] The multiple-component phase compositions can be formulated
according to known methods for preparing pharmaceutically useful
compositions. Such pharmaceutical compositions can be adapted for
various forms of administration, such as oral, parenteral, nasal,
topical, transdermal, etc. The multiple-component phase solids of
the subject invention can be made into solutions or amorphous
compounds, as injections, pills, or inhalants, for example.
Optionally, the pharmaceutical compositions can include a
pharmaceutically acceptable carrier or diluent. Formulations are
described in a number of sources which are well known and readily
available to those skilled in the art. For example, Remington's
Pharmaceutical Science (Martin EW [1995] Easton, Pa., Mack
Publishing Company, 19.sup.th ed.) describes formulations that can
be used in connection with the subject invention. Formulations
suitable for administration include, for example, aqueous sterile
injection solutions, which may contain antioxidants, buffers,
bacteriostats, and solutes which render the formulation isotonic
with the blood of the intended recipient; and aqueous and
nonaqueous sterile suspensions which may include suspending agents
and thickening agents. The formulations may be presented in
unit-dose or multi-dose containers, for example sealed ampoules and
vials, and may be stored in a freeze dried (lyophilized) condition
requiring only the condition of the sterile liquid carrier, for
example, water for injections, prior to use. Extemporaneous
injection solutions and suspensions may be prepared from sterile
powder, granules, or tablets of the multiple-component phase
compositions of the subject invention, for example. It should be
understood that in addition to the ingredients particularly
mentioned above, the formulations of the subject invention can
include other agents conventional in the art having regard to the
type of formulation in question.
[0052] In terms of superstructure, three general types of compounds
generated by interaction of a pharmaceutical molecule with another
molecule include: (1) multiple-component compounds, in which
superstructure is generated by two or more molecules, both of which
are integral components of the network and complementary; (2)
clathrate inclusion compounds, in which the compounds'
superstructure is generated by self assembly of one or more
molecules and a guest molecules is enclosed within the
superstructure; and (3) porous inclusion compounds, in which the
superstructure is open framework in nature.
[0053] The subject invention concerns multiple-component
compositions, and it is demonstrated herein that the concepts of
crystal engineering and supramolecular synthons can be applied to
prepare a wide range of novel pharmaceutical materials that are
based on rational design. Therefore, the multiple-component
compounds of the subject invention can be generated in such a
fashion that they have desirable composition, structure and
properties. More specifically, an issue that is particularly
relevant to pharmaceutical compositions of matter and processing is
addressed by the subject invention; the diversity of compositions,
superstructures and solubilities that can be generated when drug
molecules form multiple-component phases with complementary
molecules. Multiple-component phases involving the following drugs
are exemplified herein: aspirin, acetaminophen, ibuprofen (and
related compounds), phenytoin and carbamazepine and appropriate
molecular additives. These novel phases include both "model
multiple-component phases" that illustrate the concept of crystal
engineering and multiple-component phases that incorporate
pharmaceuticals with "GRAS" compounds, that is, compounds
"Generally Regarded as Safe by the FDA", and/or food additives.
[0054] In the context of organic and pharmaceutical solids, the
subject invention addresses these issues by demonstrating that
crystal engineering offers a paradigm for the supramolecular
synthesis (Chang, Y. L. et al., J. Am. Chem. Soc., 1993,
115:5991-6000) of a wide range of new multiple-component phases
that have predetermined compositions and, in some instances,
predetermined topology. Such an ability to build hierarchical
structures from molecular or supramolecular modules facilitates
precise control of structure and function of solid phases. These
multiple-component phases have the following advantages over single
component phases and traditional multiple-component phases (solid
dispersions): high thermodynamic stability (thereby reducing
problems associated with solid phase transformations), modified
bioavailability (finely tunable solubility and delivery), and
enhanced processability (crystal morphology, mechanical properties,
hygroscopicity).
[0055] The subject invention has the following implications from a
scientific perspective: (a) protocols are now available for the
rational design of a new generation of pharmaceutical phases that
contain at least two components that are sustained by
supramolecular synthons; (b) correlation of structure and function
of the new pharmaceutical phases via characterization of structure,
crystal energy, solubility, dissolution rate, and stability is now
possible; and (c) a new range of novel phases for the treatment of
pathological conditions in humans and animals are available.
[0056] The subject invention extends the state-of-the-art in at
least three ways: (1) by generating a rational, supramolecular
strategy for the design of novel, multiple-component crystalline
phases; (2) by extending this strategy to pharmaceutical phases;
and (3) by using this strategy to control the delivery properties
and stability of pharmaceutical compounds.
[0057] The following pages describe examples of multiple-component
crystalline phases that have been characterized using single
crystal X-ray crystallography and structure-sensitive analytical
techniques: FT-IR, XRPD, DSC, TGA. They represent prototypal
examples of the invention as they are all based upon pharmaceutical
molecules that are inherently predisposed to form supramolecular
synthons with other complementary functional groups, They were
chosen for study because of well-known limitations in their
solubility/bioavailibility. In each example, the nature of the pure
phase is discussed and it is sustained by a supramolecular
homosynthon (self-complementary functionalities). The
multiple-component phases prepared confirm the ability to
persistently and rationally disrupt the homosynthon by judicious
choice of a second molecular component that is predisposed to form
a supramolecular heterosynthon. That these new solid phases will
have different solubility profiles than their pure phases is to be
expected. Examples designated as GRAS are those in which second a
component that is "Generally Regarded as Safe by the FDA" was
used.
Example 1
Multi-Component Crystal of
Acetaminophen:Acetominophen/4,4'-Bipyridine/Water (1:1:1
Stoichiometry)
[0058] 50 mg (0.3307 mmol) acetaminophen and 52 mg (0.3329 mmol)
4,4'-bipyridine were dissolved in hot water and allowed to stand.
Slow evaporation yielded colorless needles of a 1:1:1
acetaminophen/4,4'-bipyridine/water co-crystal, as shown in FIG.
4B.
[0059] Crystal data: (Bruker SMART-APEX CCD Diffractometer).
C.sub.36H.sub.44N.sub.2O.sub.4, M=339.84, triclinic, space group P
; a=7.0534(8), b=9.5955(12), c=19.3649(2) .ANG., .alpha.=86.326(2),
.beta.=80.291(2), .gamma.=88.880(2).degree., U=1308.1(3)
.ANG..sup.3, T=200(2) K, Z=2, .mu.(Mo-K.alpha.)=0.090 mm.sup.-1,
D.sub.c=1.294 Mg/m.sup.3, .lamda.=0.71073 .ANG..sup.3, F(000)=537,
2.theta..sub.max=25.02.degree.; 6289 reflections measured, 4481
unique (R.sub.int=0.0261). Final residuals for 344 parameters were
R.sub.1=0.0751, wR.sub.2=0.2082 for I>2.sigma.(I), and
R.sub.1=0.1119, wR.sub.2=0.2377 for all 4481 data.
[0060] Crystal packing: The co-crystals contain bilayered sheets in
which water molecules act as a hydrogen bonded bridge between the
network bipyridine moieties and the acetaminophen. Bipyridine
guests are sustained by .pi.-.pi. stacking interactions between two
network bipyridines. The layers stack via .pi.-.pi. interactions
between the phenyl groups of the acetaminophen moieties.
[0061] Differential Scanning calorimetry: (TA Instruments 2920
DSC), 57.77.degree. C. (endotherm); m.p.=58-60.degree. C.
(MEL-TEMP); (acetaminophen m.p.=169.degree. C., 4,4'-bipyridine
m.p.=111-114.degree. C.).
Example 2
Multi-Component Crystal of Phenytoin:Phenytoin/Pyridone (1:1
Stoichiometry)
[0062] 28 mg (0.1109 mmol) phenytoin and 11 mg (0.1156 mmol)
4-hydroxypyridone were dissolved in 2 mL acetone and 1 mL ethanol
with heating and stirring. Slow evaporation yielded colorless
needles of a 1:1 phenytoin/pyridone co-crystal, as shown in FIG.
5B.
[0063] Crystal data: (Bruker SMART-APEX CCD (Diffractometer),
C.sub.20H.sub.17N.sub.3O.sub.3, M=347.37, monoclinic P2.sub.l/c;
a=16.6583(19), b=8.4878(10), c=11.9546(14) .ANG.,
.beta.=96.618(2).degree., U=1750.2(3) .ANG..sup.3, T=200(2) K, Z=4,
.mu.(Mo-K.alpha.)=0.091 mm.sup.-1, D.sub.c=1.318 Mg/m.sup.3,
.lamda.=0.71073 .ANG..sup.3, F(000)=728,
2.theta..sub.max=56.60.degree.; 10605 reflections measured, 4154
unique (R.sub.int=0.0313). Final residuals for 247 parameters were
R.sub.1=0.0560, wR.sub.2=0.1356 for I>2.sigma.(I), and
R.sub.1=0.0816, wR.sub.2=0.1559 for all 4154 data.
[0064] Crystal packing: The co-crystal is sustained by hydrogen
bonding of adjacent phentoin molecules between the carbonyl and the
amine closest to the tetrahedral carbon, and by hydrogen bonding
between pyridone carbonyl functionalities and the amine not
involved in phenytoin-phenytoin interactions. The pyridone carbonyl
also hydrogen bonds with adjacent pyridone molecules forming a
one-dimensional network.
[0065] Infrared Spectroscopy: (Nicolet Avatar 320 FTIR),
characteristic peaks for the co-crystal were identified as:
2.degree. amine found at 3311 cm.sup.-1, carbonyl (ketone) found at
1711 cm.sup.-1, olephin peak found at 1390 cm.sup.-1.
[0066] Differential Scanning calorimetry: (TA instruments 2920
DSC), 233.39.degree. C. (endotherm) and 271.33.degree. C.
(endotherm); m.p.=231-233.degree. C. (MEL-TEMP); (phenytoin
m.p.=295.degree. C., pyridone m.p.=148.degree. C.).
[0067] Thermogravimetric Analysis: (TA Instruments 2950
Hi-Resolution TGA), a 29.09% weight loss starting at 192.80.degree.
C., 48.72% weight loss starting at 238.27.degree. C., and 18.38%
loss starting at 260.17.degree. C. followed by complete
decomposition.
[0068] X-ray powder diffraction: (Rigaku Miniflex Diffractometer
using Cu K.alpha. (.lamda.=1.540562), 30 kV, 15 mA). The powder
data were collected over an angular range of 3.degree. to
40.degree. 2.theta. in continuous scan mode using a step size of
0.02.degree. 2.theta. and a scan speed of 2.0.degree./minute, XRPD:
Showed analogous peaks to the simulated XRPD derived from the
single crystal data. In all cases of recrystallization and solid
state reaction, experimental (calculated): 5.2 (5.3); 11.1 (11.3);
15.1 (15.2); 16.2 (16.4); 16.7 (17.0); 17.8 (17.9); 19.4 (19.4);
19.8 (19.7); 20.3 (20.1); 21.2 (21.4); 23.3 (23.7); 26.1 (26.4);
26.4 (26.6); 27.3 (27.6); 29.5 (29.9).
Example 3
Multi-Component Crystal of Aspirin (Acetylsalicylic
Acid):Aspirin/4,4'-bipyridine (2:1 Stoichiometry)
[0069] 50 mg (0.2775 mmol) aspirin and 22 mg (0.1388 mmol)
4,4'-bipyridine were dissolved in 4 mL hexane. 8 mL ether was added
to the solution and allowed to stand for one hour, yielding
colorless needles of a 2:1 aspirin/4,4'-bipyridine co-crystal, as
shown in FIG. 6D. Alternatively, aspirin/4,4'-bipyridine (2:1
stoichiometry) can be made by grinding the solid ingredients in a
pestle and mortar.
[0070] Crystal data: (Bruker SMART-APEX CCD Diffractometer),
N.sub.2O.sub.8, M=516.49, orthorhombic Pbcn; a=28.831(3),
b=11.3861(12), c=8.4144(9) .ANG., U=2762.2(5) .ANG..sup.3, T=173(2)
K, Z=4, .mu.(Mo-K.alpha.)=0.092 mm.sup.-1, D.sub.c=1.242
Mg/m.sup.3, .lamda.=0.71073 .ANG..sup.3, F(000)=1080,
2.theta..sub.max=25.02.degree.; 12431 reflections measured, 2433
unique (R.sub.int=0.0419). Final residuals for 202 parameters were
R.sub.10.0419, wR.sub.2=0.1358 for I>2.sigma.(I), and
R.sub.1=0.0541, wR.sub.2=0.1482 for all 2433 data.
[0071] Crystal packing: The co-crystal contains the carboxylic
acid-pyridine heterodimer that crystallizes in the Pbcn space
group. The structure is an inclusion compound containing disordered
solvent in the channels. In addition to the dominant hydrogen
bonding interaction of the heterodimer, .pi.-.pi. stacking of the
bipyridine and phenyl groups of the aspirin and hydrophobic
interactions contribute to the overall packing interactions.
[0072] Infrared Spectroscopy: (Nicolet Avatar 320 FTIR),
characteristic (--COOH) peak at 1679 cm.sup.-1 was shifted up and
less intense at 1694 cm.sup.-1, where as the lactone peak is
shifted down slightly from 1750 cm.sup.-1 to 1744 cm.sup.-1.
[0073] Differential Scanning calorimetry: (TA Instruments 2920
DSC), 95.14.degree. C. (endotherm); m.p.=91-96.degree. C.
(MEL-TEMP); (aspirin m.p. 1345.degree. C., 4,4'-bipyridine
m.p.=111-114.degree. C.).
[0074] Thermogravimetric Analysis: (TA Instruments 2950
Hi-Resolution TGA), weight loss of 9% starting at 22.62.degree. C.,
49.06% weight loss starting at 102.97.degree. C. followed by
complete decomposition starting at 209.37.degree. C.
Example 4
Multi-Component Crystal of Ibuprofen:Ibuprofen/4,4'-Bipyridine (2:1
Stoichiometry)
[0075] 50 mg (0.242 mmol) racemic ibuprofen and 18 mg (0.0960 mmol)
4,4'-bipyridine were dissolved in 5 mL acetone. Slow evaporation of
the solvent yielded colorless needles of a 2:1
ibuprofen/4,4'-bipyridine co-crystal, as shown in FIG. 7D.
[0076] Crystal data: (Bruker SMART-APEX CCD Diffractometer),
C.sub.36H.sub.44N.sub.2O.sub.4, M=568.73, triclinic, space group
P-1; a=5.759(3), b=11.683(6), c=24.705(11) .ANG.,
.alpha.=93.674(11), .beta.=90.880(10), .gamma.=104.045(7).degree.,
U=1608.3(13) .ANG..sup.3, T=200(2) K, Z=2, .mu.(Mo-K.alpha.)=0.076
mm.sup.-1, D.sub.c=1.174 Mg/m.sup.3, .lamda.=0.71073 .ANG..sup.3,
F(000)=612, 2.theta..sub.max=23.29.degree.; 5208 reflections
measured, 3362 unique (R.sub.int=0.0826). Final residuals for 399
parameters were R.sub.1=0.0964, wR.sub.2=0.2510 for
I>2.sigma.(I), and R.sub.1=0.1775, wR.sub.2=0.2987 for all 3362
data.
[0077] Crystal packing: The co-crystal contains ibuprofen
bipyridine heterodimers, sustained by two hydrogen bonded
carboxylic acidpyridine supramolecular synthons, arranged in a
herringbone motif that packs in the space group P-1. The
heterodimer is an extended version of the homodimer and packs to
form a two-dimensional network sustained by .pi.-.pi. stacking of
the bipyridine and phenyl groups of the ibuprofen and hydrophobic
interactions from the ibuprofen tails.
[0078] Infrared Spectroscopy: (Nicolet Avatar 320 FTIR). Analysis
observed stretching of aromatic C--H at 2899 cm.sup.-1; bending and
scissoring at 1886 cm.sub.-1; C.dbd.O stretching at 1679 cm.sup.-1;
C--H out-of-plane bending for both 4,4'-bipyridine and ibuprofen at
808 cm.sup.-1 and 628 cm.sup.-1.
[0079] Differential Scanning calorimetry: (TA Instruments 2920
DSC), 64.85.degree. C. (endotherm) and 118.79.degree. C.
(endotherm); 113-120.degree. C. (MEL-TEMP); (ibuprofen
m.p.=75-77.degree. C., 4,4'-bipyridine m.p.=111-114.degree.
C.).
[0080] Thermogravimetric Analysis: (TA Instruments 2930
Hi-Resolution TGA), 13.28% weight loss between room temperature and
100.02.degree. C. immediately followed by complete
decomposition.
[0081] X-ray powder diffraction: (Rigaku Miniflex Diffractometer
using Cu K.alpha. (.lamda.=1.540562), 30 kV, 15 mA). The powder
data were collected over an angular range of 3.degree. to
40.degree. 2.theta. in continuous scan mode using a step size of
0.02.degree. 2.theta. and a scan speed of 2.0.degree./minute. XRPD
derived from the single crystal data, experimental (calculated):
3.4 (3.6); 6.9 (7.2); 10.4 (10.8); 17.3 (17.5); 19.1 (19.7).
Example 5
Multi-Component Crystal of
Flurbiprofen:Flurbiprofen/4,4'-bipyridine (2:1 Stoichiometry)
[0082] 50 mg (0.2046 mmol) flurbiprofen and 15 mg (0.0960 mmol)
4,4'-bipyridine were dissolved in 3 mL acetone. Slow evaporation of
the solvent yielded colorless needles of a 2:1
flurbiprofen/4,4'-bipyridine co-crystal, as shown in FIG. 8D.
[0083] Crystal data: (Bruker SMART-APEX CCD Diffractometer),
C.sub.40H.sub.34F.sub.2N.sub.2O.sub.4, M=644.69, monoclinic
P2.sub.l/n; a=5.860(4), b=47.49(3), c=5.928(4) .ANG.,
.beta.=107.382 (8).degree., U=1574.3(19) .ANG..sup.3, T=200(2) K,
Z=2, .mu.(Mo-K.alpha.)=0.096 mm.sup.-1, D.sub.c=1.360 Mg m.sup.3,
.lamda.=0.71073 .ANG..sup.3, F(000)=676,
2.theta..sub.max=21.69.degree.; 4246 reflections measured, 1634
unique (R.sub.int=0.0677). Final residuals for 226 parameters were
R.sub.1=0.0908, wR.sub.2=0.2065 for I>2.sigma.(I), and
R.sub.1=0.1084, wR.sub.2=0.2209 for all 1634 data.
[0084] Crystal packing: The co-crystal contains
flurbiprofen/bipyridine heterodimers, sustained by two hydrogen
bonded carboxylic acidpyridine supramolecular synthon, arranged in
a herringbone motif that packs in the space group P2.sub.l/n. The
heterodimer is an extended version of the homodimer and packs to
form a two-dimensional network sustained by .pi.-.pi. stacking and
hydrophobic interactions of the bipyridine and phenyl groups of the
flurbiprofen.
[0085] Infrared Spectroscopy: (Nicolet Avatar 320 FTIR), aromatic
C--H stretching at 3057 cm.sup.-1 and 2981 cm.sup.-1; N--H bending
and scissoring at 1886 cm.sup.-1; C.dbd.O stretching at 1690
cm.sup.-1; C.dbd.C and C.dbd.N ring stretching at 1418
cm.sup.-1.
[0086] Differential Scanning calorimetry: (TA Instruments 2920
DSC), 162.47.degree. C. (endotherm); m.p.=155-160.degree. C.
(MEL-TEMP); (flurbiprofen m.p.=110-111.degree. C., 4,4'-bipyridine
m.p.=111-114.degree. C.).
[0087] Thermogravimetric Analysis: (TA Instruments 2950
Hi-Resolution TGA), 30.93% weight loss starting at 31.13.degree. C.
and a 46.26% weight loss starting at 168.74.degree. C. followed by
complete decomposition.
[0088] X-ray powder diffraction: (Rigaku Miniflex Diffractometer
using Cu K.alpha. (.lamda.=1.540562), 30 kV, 15 mA), the powder
data were collected over an angular range of 3.degree. to
40.degree. 2.theta. in continuous scan mode using a step size of
0.02.degree. 2.theta. and a scan speed of 2.0.degree./minute. XRPD
derived from the single crystal data: experimental (calculated):
16.8 (16.8); 17.1 (17.5); 18.1 (18.4); 19.0 (19.0); 20.0 (20.4);
21.3 (21.7); 22.7 (23.0); 25.0 (25.6); 26.0 (26.1); 26.0 (26.6);
26.1 (27.5); 28.2 (28.7); 29.1 (29.7).
Example 6
Multi-Component Crystal of
Flurbiprofen:Flurbiprofen/trans-1,2-bis(4-pyridyl)ethylene (2:1
Stoichiometry).
[0089] 25 mg (0.1023 mmol) flurbiprofen and 10 mg (0.0548 mmol)
trans-1,2-bis(4-pyridyl) ethylene were dissolved in 3 mL acetone.
Slow evaporation of the solvent yielded colorless needles of a 2:1
flurbiprofen/1,2-bis(4-pyridyl) ethylene co-crystal, as shown in
FIG. 9B.
[0090] Crystal data: (Breaker SMART-APEX CCD Diffractometer),
C.sub.42H.sub.36F.sub.2N.sub.2O,.sub.4, M=670.73, monoclinic
P2.sub.l/n; a=5.8697(9), b=47.357(7), c=6.3587(10) .ANG.,
.beta.=109.492(3).degree., U=1666.2(4) .ANG..sup.3, T=200(2) K,
Z=2, .mu.(Mo-K.alpha.)=0.093 mm.sup.-1, D.sub.c=1.337 Mg/m.sup.3,
.lamda.=0.71073 .ANG..sup.3, F(000)=704,
2.theta..sub.max=21.69.degree., 6977 reflections measured, 2383
unique (R.sub.int=0.0383). Final residuals for 238 parameters were
R.sub.1=0.0686, wR.sub.2=0.1395 for I>2.sigma.(I), and
R.sub.1=0.1403, wR.sub.2=0.1709 for all 2383 data.
[0091] Crystal packing: The co-crystal contains
flurbiprofen/1,2-bis(4-pyridyl)ethylene heterodimers, sustained by
two hydrogen bonded carboxylic acid-pyridine supramolecular
synthons, arranged in a herringbone motif that packs in the space
group P2.sub.l/n. The heterodimer from 1,2-bis(4-pyridyl)ethylene
further extends the homodimer relative to example 5 and packs to
form a two-dimensional network sustained by .pi.-.pi. stacking and
hydrophobic interactions of the bipyridine and phenyl groups of the
flurbiprofen.
[0092] Infrared Spectroscopy: (Nicolet Avatar 320 FTIR), aromatic
C--H stretching at 2927 cm.sup.-1 and 2850 cm.sup.-1; N--H bending
and scissoring at 1875 cm.sup.-1; C.dbd.O stretching at 1707
cm.sup.-1; C.dbd.C and C.dbd.N ring stretching at 1483
cm.sup.-1.
[0093] Differential Scanning calorimetry: (TA Instruments 2920
DSC), 100.01.degree. C., 125.59.degree. C. and 163.54.degree. C.
(endotherms); m.p.=153-158.degree. C. (MEL-TEMP); (flurbiprofen
m.p.=110-111.degree. C., trans-1,2-bis(4-pyridyl) ethylene
m.p.=150-153.degree. C.).
[0094] Thermogravimetric Analysis: (TA Instruments 2950
Hi-Resolution TGA), 91.79% weight loss starting at 133.18.degree.
C. followed by complete decomposition.
[0095] X-ray powder diffraction: (Rigaku Miniflex Diffractometer
using Cu K.alpha. (.lamda.=1.540562), 30 kV, 15 mA), the powder
data were collected over an angular range of 3.degree. to
40.degree. 2.theta. in continuous scan mode using a step size of
0.02.degree. 2.theta. and a scan speed of 2.0.degree./minute. XRPD
derived from the single crystal data, experimental (calculated):
3.6 (3.7); 17.3 (17,7); 18.1 (18.6); 18.4 (18.6); 19.1 (19.3); 22.3
(22.5); 23.8 (23.9); 25.9 (26.4); 28.1 (28.5).
Example 7
Multi-Component Crystal of
Carbamazepine:Carbamazepine/p-Phthalaldehyde (1:1
Stoichiometry)
[0096] 25 mg (0.1058 mmol) carbamazepine and 7 mg (0.0521 mmol)
p-phthalaldehyde were dissolved in approximately 3 mL methanol.
Slow evaporation of the solvent yielded colorless needles of a 1:1
carbamazepine/p-phthalaldehyde co-crystal, as shown in FIG.
10B.
[0097] Crystal data: (Bruker SMART-APEX CCD Diffractometer),
C.sub.38H.sub.30N.sub.4O.sub.4, M 606.66, monoclinic C2/c;
a=29.191(16), b=4.962(3), c=20.316(11) .ANG.,
.beta.=92.105(8).degree., U=2941(3) .ANG..sup.3, T=200(2) K, Z=4,
.mu.(Mo-K.alpha.)=0.090 mm.sup.-1, D.sub.c=1.370 Mg/m.sup.3,
.lamda.=0.71073 .ANG..sup.3, F(000)=1272,
2.theta..sub.max=43.66.degree., 3831 reflections measured, 1559
unique (R.sub.int=0.0510). Final residuals for 268 parameters were
R.sub.f=0.0332, wR.sub.2=0.0801 for I>2.sigma.(I), and
R.sub.1=0.0403, wR.sub.2=0.0831 for all 1559 data.
[0098] Crystal packing: The co-crystals contain hydrogen bonded
carboxamide homodimers that crystallize in the space group C2/c.
The 1.degree. amines of the homodimer are bifurcated to the
carbonyl of the p-phthalaldehyde forming a chain with an adjacent
homodimer. The chains pack in a crinkled tape motif sustained by
.pi.-.pi. interactions between phenyl rings of the CBZ.
[0099] Infrared Spectroscopy: (Nicolet Avatar 320 FTIR). The
1.degree. amine unsymmetrical and symmetrical stretching was
shifted down to 3418 cm.sup.-1; aliphatic aldehyde and 1.degree.
amide C.dbd.O stretching was shifted up to 1690 cm.sup.-1; N--H
in-plane bending at 1669 cm.sup.-1; C--H aldehyde stretching at
2861 cm.sup.-1 and H--C.dbd.O bending at 1391 cm.sup.-1.
[0100] Differential Scanning calorimetry: (TA Instruments 2920
DSC), 128.46.degree. C. (endotherm), m.p.=121-124.degree. C.
(MEL-TEMP), (carbamazepine m.p. 190.2.degree. C., p-phthalaldehyde
m.p. 116.degree. C.).
[0101] Thermogravimetric Analysis: (TA Instruments 2950
Hi-Resolution TGA), 17.66% weight loss starting at 30.33.degree. C.
then a 17.57% weight loss starting at 100.14.degree. C. followed by
complete decomposition.
[0102] X-ray powder diffraction: (Rigaku Miniflex Diffractometer
using Cu K.alpha. (.lamda.=1.540562), 30 kV, 15 mA). The powder
data were collected over an angular range of 3.degree. to
40.degree. 2.theta. in continuous scan mode using a step size of
0.02.degree. 2.theta. and a scan speed of 2.0.degree./minute. XRPD
derived from the single crystal data, experimental (calculated):
8.5 (8.7); 10.6 (10.8); 11.9 (12.1); 14.4 (14.7) 15.1 (15.2); 18.0
(18.1); 18.5 (182); 19.8 (18.7); 23.7 (24.0); 24.2 (24.2); 26.4
(26.7); 27.6 (27.9); 27.8 (28.2); 28.7 (29.1); 29.3 (29.6); 29.4
(29.8).
Example 8
Multi-Component Crystal of Carbamazepine:Carbamazepine/Nicotinamide
(GRAS) (1:1 Stoichiometry)
[0103] 25 mg (0.1058 mmol) carbamazepine and 12 mg (0.0982 mmol)
nicotinamide were dissolved in 4 mL of DMSO, methanol or ethanol.
Slow evaporation of the solvent yielded colorless needles of a 1:1
carbamazepine/nicotinamide co-crystal, as shown in FIG. 11.
[0104] Using a separate method, 25 mg (0.1058 mmol) carbamazepine
and 12 mg (0.0982 mmol) nicotinamide were ground together with
mortar and pestle. The solid was determined to be 1:1
carbamazepine/nicotinamide microcrystals (XPD).
[0105] Crystal data: (Bruker SMART-APEX CCD Diffractometer),
C.sub.21H.sub.18N.sub.4O.sub.2, M=358.39, monoclinic P2.sub.l/n;
a=5.0961(8), b=17.595(3), c=19.647(3) .ANG.,
.beta.=90.917(3).degree., U=1761.5(5) .ANG..sup.3, T=200(2) K, Z=4,
.mu.(Mo-K.alpha.)=0.090 D.sub.c=1.351 Mg/mm.sup.3, .lamda.=0.71073
.ANG..sup.3, F(000)=752, 2.theta..sub.max=56.60.degree., 10919
reflections measured, 4041 unique (R.sub.int=0.0514). Final
residuals for 248 parameters were R.sub.1=0.0732, wR.sub.2=0.1268
for I>2.sigma.(I), and R.sub.1=0.1161, wR.sub.2=0.1430 for all
4041 data.
[0106] Crystal packing: The co-crystals contain hydrogen bonded
carboxamide homodimers. The 1.degree. amines are bifurcated to the
carbonyl of the nicotinamide on each side of the dimer. The
1.degree. amines of each nicotinamide are hydrogen bonded to the
carbonyl of the adjoining dimer. The dimers form chains with
.pi.-.pi. interactions from the phenyl groups of the CBZ.
[0107] Infrared Spectroscopy: (Nicolet Avatar 320 FTIR),
unsymmetrical and symmetrical stretching shifts down to 3443
cm.sup.-1 and 3388 cm.sup.-1 accounting for 1.degree. amines;
1.degree. amide C.dbd.O stretching at 1690 cm.sup.-1; N--H in-plane
bending at 1614 cm.sup.-1; C.dbd.C stretching shifted down to 1579
cm.sup.-1; aromatic H's from 800 cm.sup.-1 to 500 cm.sup.-1 are
present.
[0108] Differential Scanning calorimetry: (TA Instruments 2920
DSC), 74.49.degree. C. (endotherm) and 59.05.degree. C.
(endotherm), m.p.=153-158.degree. C. (MEL-TEMP), (carbamazepine
m.p.=190.2.degree. C., nicotinamide m.p.=150-160.degree. C.).
[0109] Thermogravimetric Analysis: (TA Instruments 2950
Hi-Resolution TGA), 57.94% weight loss starting at 205.43.degree.
C. followed by complete decomposition.
[0110] X-ray powder diffraction: (Rigaku Miniflex Diffractometer
using Cu K.alpha. (.lamda.=1.540562), 30 kV, 15 mA). The powder
data were collected over an angular range of 3.degree. to
40.degree. 2.theta. in continuous scan mode using a step size of
0.02.degree. 2.theta. and a scan speed of 2.0.degree./minute. XRPD:
Showed analogous peaks to the simulated XRPD derived from the
single crystal data. XRPD analysis experimental (calculated): 6.5
(6.7); 8.8 (9.0); 10.1 (10.3); 13.2 (13.5); 15.6 (15.8); 17.7
(17.9); 17.8 (18.1); 18.3 (18.6); 19.8 (20.1); 20.4 (20.7); 21.6
(22.); 22,6 (22.8); 22.9 (23.2); 26.4 (26.7); 26.7 (27.0); 28.0
(28.4).
Example 9
Multi-Component Crystal of Carbamazepine:Carbamazepine/Saccharin
(GRAs) (1:1 Stoichiometry)
[0111] 25 mg (0.1058 mmol) carbamazepine and 19 mg (0.1037 mmol)
saccharin were dissolved in approximately 4 mL ethanol. Slow
evaporation of the solvent yielded colorless needles of a 1:1
carbamazepine/saccharin cocrystal, as shown in FIG. 12. Solubility
measurements indicate that this multiple-component crystal of
carbamazepine has improved solubility over previously known forms
of carbamazepine (e.g., increased molar solubility and longer
solubility in aqueous solutions).
[0112] Crystal data: (Bruker SMART-APEX CCD Diffractometer),
C.sub.2211.sub.17N.sub.3O.sub.4S M=419.45, triclinic P-1;
a=7.5140(11), b=10.4538(15), c=12.6826(18) .ANG.,
.alpha.=83.642(2).degree., .beta.=85.697(2).degree.,
.gamma.=75.411(2).degree., U=957.0(2) .ANG..sup.3, T=200(2) K, Z=2,
.mu.(Mo-K.alpha.)=0.206 mm.sup.-1, D.sub.c=1.456 Mg/m.sup.3,
.lamda.=0.71073 .ANG..sup.3, F(000)=436,
2.theta..sub.max=56.20.degree.; 8426 reflections measured, 4372
unique (R.sub.int=0.0305). Final residuals for 283 parameters were
R.sub.1=0.0458, wR.sub.2=0.1142 for I>2.sigma.(I), and
R.sub.1=0.0562, wR.sub.20.1204 for all 4372 data.
[0113] Crystal packing: The co-crystals contain hydrogen bonded
carboxamide homodimers. The 2.degree. amines of the saccharin are
hydrogen bonded to the carbonyl of the CBZ on each side forming a
tetramer. The crystal has a space group of P-1 with .pi.-.pi.
interactions between the phenyl groups of the CBZ and the saccharin
phenyl groups.
[0114] Infrared Spectroscopy: (Nicolet Avatar 320 FTIR),
unsymmetrical and symmetrical stretching shifts up to 3495
cm.sup.-1 accounting for 1.degree. amines; C.dbd.O aliphatic
stretching was shifted up to 1726 cm.sup.-1; N--H in-plane bending
at 1649 cm.sup.-1; C.dbd.C stretching shifted down to 1561
cm.sup.-1; (O.dbd.S.dbd.O) sulfonyl peak at 1330 cm.sup.-1 C--N
aliphatic stretching 1175 cm.sup.-1.
[0115] Differential Scanning calorimetry: (TA Instruments 2920
DSC), 75.31.degree. C. (endotherm) and 177.32.degree. C.
(endotherm), m.p.=148-155.degree. C. (MEL-TEMP); (carbamazepine
m.p.=190.2.degree. C., saccharin m.p.=228.8.degree. C.).
[0116] Thermogravimetric Analysis: (TA Instruments 2950
Hi-Resolution TGA), 3.342% weight loss starting at 67.03.degree. C.
and a 55.09% weight loss starting at 118.71.degree. C. followed by
complete decomposition.
[0117] X-ray powder diffraction: (Rigaku Miniflex Diffractometer
using Cu K.alpha. (.lamda.=1.540562), 30 kV, 15 mA). The powder
data were collected over an angular range of 3.degree. to
40.degree. 2.theta. in continuous scan mode using a step size of
0.02.degree. 2.theta. and a scan speed of 2.0.degree. /minute. XRPD
derived from the single crystal data, experimental (calculated):
6.9 (7.0); 12.2 (12.2); 13.6 (13.8); 14,0 (14.1); 14.1 (14.4); 15.3
(15.6); 15.9 (15.9); 18.1 (18.2); 18.7 (18.8); 20.2 (20.3); 2.1.3
(21.5); 23.7 (23.9); 26.3 (26.4); 28.3 (28.3).
Example 10
Multi-Component Crystal of
Carbamazenine:Carbamazepine/2,6-pyridinedicarboxylic Acid (2:3
Stoichiometry)
[0118] 36 mg (0.1524 mmol) carbamazepine and 26 mg (0.1556 mmol)
2,6-pyridinedicarboxylic acid were dissolved in approximately 2
ethanol. Slow evaporation of the solvent yielded clear needles of a
1:1 carbamazepine/2,6-pyridinedicarboxylic acid co-crystal, as
shown in FIG. 14B.
[0119] Crystal data: (Bruker SMART-APEX CCD Diffractometer),
C.sub.2H.sub.17N.sub.3O.sub.5, M=403.39, orthorhombic
P2(1)2(1)2(1); 7.2122, b=14.6491, c=17.5864 .ANG.,
.alpha.=90.degree., .beta.=90.degree., .gamma.=90.degree.,
V=1858.0(2) .ANG..sup.3, T=100 K, Z=4, .mu.(MO-K.alpha.)=0.104
mm.sup.-1, D.sub.c=1.442 Mg/m.sup.3, .lamda.=0.71073 .ANG..sup.3,
F(000)840, 2.theta..sub.max=28.3. 16641 reflections measured, 4466
unique (R.sub.int=0.093). Final residuals for 271 parameters were
R.sub.1=00425 and wR.sub.2=0.0944 for I>2.sigma.(I).
[0120] Crystal packing: Each hydrogen on the CBZ 1.degree. amine is
hydrogen bonded to a carbonyl group of a different
2,6-pyridinedicarboxylic acid moiety. The carbonyl of the CBZ
carboxamide is hydrogen bonded to two hydroxide groups of one
2,6-pyridinedicarboxylic acid moiety.
[0121] Infrared Spectroscopy: (Nicolet Avatar 320 FTIR). 3439
cm.sup.-1, (N--H stretch, 1.degree. amine, CBZ); 1734 cm.sup.1,
(C.dbd.O); 1649 cm.sup.-1, (C.dbd.C).
[0122] Melting Point: 214-216.degree. C. (MEL-TEMP). (carbamazepine
m.p.=191-192.degree. C., 2,6-pyridinedicarboxylic acid
m.p.=248-250.degree. C.),
[0123] Thermogravimetric Analysis: (TA Instruments 2950
Hi-Resolution TGA). 69% weight loss starting at 215.degree. C. and
a 17% weight loss starting at 392.degree. followed by complete
decomposition.
Example 11
Multi-Component Crystal of
Carbamazepine:Carbamazepine/5-nitroisophthalic acid (1:1
Stoichiometry)
[0124] 40 mg (0.1693 mmol) carbamazepine and 30 mg (0.1421 mmol)
5-nitroisophthalic acid were dissolved in approximately 3 mL
methanol or ethanol. Slow evaporation of the solvent yielded yellow
needles of a 1:1 carbamazepine/5-nitroisophthalic acid co-crystal,
as shown in FIG. 15B.
[0125] Crystal data: (Broker SMART-APEX CCD Diffractometer).
C.sub.47H.sub.40N.sub.6O.sub.16, M=944.85, monoclinic C2/c;
a=34.355(8), b=5.3795(13), c=23.654(6) .ANG., .alpha.=90.degree.,
.beta.=93.952(6).degree., .gamma.=90.degree.,
V=4361.2(18).ANG..sup.3, T=200(2) K, Z=4, .mu.(MO-K.alpha.)=0.110
mm.sup.-1, D.sub.c=1.439 Mg/m.sup.3, .lamda.=0.71073 .ANG..sup.3,
F(000)1968, 2.theta..sub.max=26.43.degree.. 11581 reflections
measured, 4459 unique (R.sub.int=0.0611). Final residuals for 311
parameters were R.sub.1=0.0725, wR.sub.2=0.1801 for
I>2.sigma.(I), and R.sub.1=0.1441, wR.sub.w=0.1204 for all 4459
data.
[0126] Crystal packing: The co-crystals are sustained by hydrogen
bonded carboxylic acid homodimers between the two
5-nitroisophthalic acid moieties and hydrogen bonded carboxy-amide
heterodimers between the carbamazepine and 5-nitroisophthalic acid
moiety There is solvent hydrogen bonded to an additional N--H donor
from the carbamazepine moiety.
[0127] Infrared Spectroscopy: (Nicolet Avatar 320 FTIR). 3470
cm.sup.-1, (N--H stretch, 1.degree. amine, CBZ); 3178 cm.sup.-1,
(C--H stretch, alkene); 1688 cm.sup.-1, (C.dbd.O); 1602 cm.sup.-1,
(C.dbd.C).
[0128] Differential Scanning calorimetry: (TA Instruments 2920
DSC). 190.51.degree. C. (endotherm). m.p.=NA (decomposes at
197-200.degree. C.) (MEL-TEMP). (carbamazepine m.p.=191-192.degree.
C., 5-nitroisophthalic acid m.p.=260-261.degree. C.).
[0129] Thermogravimetric Analysis: (TA Instruments 2950
Hi-Resolution TGA), 32.02% weight loss starting at 202.degree., a
12.12% weight loss starting at 224.degree. and a 17.94% weight loss
starting at 285.degree. followed by complete decomposition.
[0130] X-ray powder diffraction: (Rigaku Miniflex Diffractometer
using CuK.alpha. (.lamda.=1.540562), 30 kV, 15 mA). The powder data
were collected over an angular range of 3 to 40 2 in continuous
scan mode using a step size of 0.02 2 and a scan speed of 2.0/min.
XRPD: Showed analogous peaks to the simulated XRPD derived from the
single crystal data, XRPD analysis experimental (calculated):
10.138 (10.283), 15.291 (15.607), 17.438 (17.791), 21.166 (21.685),
31.407 (31.738), 32.650 (32.729).
Example 12
Multi-Component Crystal of Carbamazepine:Carbamazepine/acetic acid
(1:1 Stoichiometry)
[0131] 25 mg (0.1058 mmol) carbamazepine was dissolved in
approximately 2 mL acetic acid. Slow evaporation of the solvent
yielded yellow needles of a 1:1 carbamazepine/acetic acid
co-crystal, as shown in FIG. 16B.
[0132] Crystal data: (Bailer SMART-APEX CCD Diffractometer),
C.sub.17H.sub.16N.sub.2O.sub.3, M=296.32, monoclinic P2(1)/c;
a=5.1206(4), b=15.7136(13), c=18.4986(15) .ANG.,
.alpha.=90.degree., .beta.=96.5460(10).degree., .gamma.=90.degree.,
V=1478.8(2).ANG..sup.3, T=100(2) K, Z=4, .mu.(MO-K.alpha.)=0.093
mm.sup.-1, D.sub.c=1.331 Mg/m.sup.3, .lamda.=0.71073 .ANG..sup.3,
F(000)624, 2.theta..sub.max=28.4.degree., 12951 reflections
measured, 3529 unique (R.sub.int=0.076). Final residuals for 203
parameters were R.sub.1=0.0492, wR.sub.2=0.1335 for
I>2.sigma.(I).
[0133] Crystal packing: The co-crystal is sustained by hydrogen
bonded carboxamide-carboxylic heterodimers. The second 1.degree.
amine hydrogen from each CBZ joins 2 heterodimers side by side
forming a tetramer.
[0134] Infrared Spectroscopy: (Nicolet Avatar 320 FTIR). 3462
cm.sup.-1, (N--H stretch, 1.degree. amine, CBZ); 1699 (C.dbd.O);
1629 cm.sup.-1, (C.dbd.C, CBZ); 1419 cm.sup.-1, (COOH, acetic
acid).
[0135] Melting Point: 187.degree. C. (MEL-TEMP). (carbamazepine
m.p.=191-192.degree. C., acetic acid m.p.=16.6.degree. C.).
[0136] Thermogravimetric Analysis: (TA Instruments 2950
Hi-Resolution TGA). 20.62% weight loss starting at 104.degree. and
a 77.05% weight loss starting at 200.degree. followed by complete
decomposition.
Example 13
Multi-Component Crystal of
Carbamazepine:Carbamazepine/1,3,5,7-Adamantanetetracarboxylic Acid
(1:1 Stoichiometry)
[0137] 15 mg (0.1524 mmol) carbamazepine and 20 mg (0.1556 mmol)
1,3,5,7-adamantanetetracarboxylic acid were dissolved in
approximately 1 mL methanol or 1 mL ethanol. Slow evaporation of
the solvent yields clear plates of a 2:1
carbamazepine/1,3,5,7-adamantanetetracarboxylic acid co-crystal, as
shown in FIG. 17B.
[0138] Crystal data: (Bruker SMART-APEX CCD Diffractometer).
C.sub.44H.sub.40N.sub.2O.sub.10, M=784.80, monoclinicC2/c;
a=18.388(4), 1)=12.682(3), c=16.429(3) .ANG.,
.beta.=100.491(6).degree., V=3767.1(14) .ANG..sup.3, T=100(2) K,
Z=4, .mu.(MO-K.alpha.)=0.099 D.sub.c=1.384 Mg/m.sup.3,
.lamda.=0.71073 .ANG..sup.3, F(000)1648,
2.theta..sub.max=28.20.degree.. 16499 reflections measured, 4481
unique (R.sub.int=0.052). Final residuals for 263 parameters were
R.sub.1=0.0433 and wR.sub.2=0.0913 for I>2.sigma.(I).
[0139] Crystal packing: The co-crystals form a single 3D network of
four tetrahedron, linked by square planes similar to the PIS
topology, The crystals are sustained by hydrogen bonding.
[0140] Infrared Spectroscopy: (Nicolet Avatar 320 FTIR), 3431
cm.sup.-1, (N--H stretch, 1.degree. amine, CBZ); 3123 cm.sup.-1,
(C--H stretch, alkene); 1723 cm.sup.-1, (C.dbd.O); 1649 cm.sup.-1,
(C.dbd.C).
[0141] Melting Point: (MEL-TEMP). 258-260.degree. C. (carbamazepine
m.p.=1.91-192.degree. C., adamantanetetracarboxylic acid
m.p.=>390.degree. C.).
[0142] Thermogravimetric Analysis: (TA Instruments 2950
Hi-Resolution TGA). 9% weight loss starting at 189.degree. C., a
52% weight loss starting at 251.degree. C. and a 31% weight loss
starting at 374.degree. C. followed by complete decomposition.
Example 14
Multi-Component Crystal of Carbamazepine:Carbamazepine/Benzoquinone
(10 Stoichiometry)
[0143] 25 mg (0.1058 mmol) carbamazepine and 11 mg (0.1018 mmol)
benzoquinone was dissolved in 2 mL methanol or THF. Slow
evaporation of the solvent produced an average yield of yellow
crystals of a 1:1 carbamazepine/benzoquinone co-crystal, as shown
in FIG. 18B.
[0144] Crystal data: (Bruker SMART-APEX CCD Diffractometer).
C.sub.21H.sub.16N.sub.2O.sub.3, M=344.36, monoclinic P2(1)/c;
a=10.3335(18), b=27,611(5), c=4.9960(9) .ANG.,
.beta.=102.275(3).degree., V=1392.9(4) .ANG..sup.3, T=100(2) K,
Z=3, D.sub.c=1.232 Mg/m.sup.3, .mu.(MO-K.alpha.)=0.084 mm.sup.-1,
.lamda.=0.71073 .ANG..sup.3, F(000)540,
2.theta..sub.max=28.24.degree.. 8392 reflections measured, 3223
unique (R.sub.int=0.1136). Final residuals for 199 parameters were
R.sub.1=0.0545 and wR.sub.2=0.1358 for I>2.sigma.(I), and
R.sub.1=0.0659 and wR.sub.2=0.1427 for all 3223 data.
[0145] Crystal packing: The co-crystals contain hydrogen bonded
carboxamide, homodimers. Each 1.degree. amine on the CBZ is
bifurcated to a carbonyl group of a benzoquinone moiety. The dimers
form infinite chains.
[0146] Infrared Spectroscopy: (Nicolet Avatar 320 FTIR). 3420
cm.sup.-1, (N--H stretch, 1.degree. amine, CBZ); 2750 cm.sup.-1,
(aldehyde stretch); 1672 cm.sup.-1, (C.dbd.O); 1637 cm.sup.-1,
(C.dbd.C, CBZ).
[0147] Melting Point: 170.degree. C. (MEL-TEMP). (carbamazepine
m.p.=191-192.degree. C., benzoquinone m.p.=115.7.degree. C.).
[0148] Thermogravimetric Analysis: (TA Instruments 2950
Hi-Resolution TGA), 20.62% weight loss starting at 168.degree. and
a 78% weight loss starting at 223.degree. followed by complete
decomposition.
Example 15
Multi-Component Crystal of Carbamazepine:Carbamazepine/butyric acid
(1:1 Stoichiometry)
[0149] 10 mg (0.0423 mmol) carbamazepine was dissolved in
approximately 1 mL butyric acid. Slow evaporation of the solvent
mixture produced an average yield of yellow/brown crystals of a 1:1
carbamazepine/butyric acid co-crystal, as shown in FIG. 19B.
[0150] Crystal data: (Bruker SMART-APEX CCD Diffractometer).
C.sub.19H.sub.20N.sub.2O.sub.3, M=324.37, triclinic P-1; a=9.1567,
b=10.1745, c=10.5116 .ANG.,.alpha.=72.850.degree.,
.beta.=70.288.degree., .gamma.=67.269.degree., V=832.17
.ANG..sup.3, T=100.degree. K, Z=2, .mu.(MO-K.alpha.)=0.088
D.sub.c=1.290 Mg/m.sup.3, .lamda.=0.71073 .ANG..sup.3, F(000)344,
2.theta..sub.max=28.28.degree.. 5315 reflections measured, 3686
unique (R.sub.int=0.0552). Final residuals for 217 parameters were
R.sub.1=0.0499, wR.sub.2=0.1137 for I>2.sigma.(I), and
R.sub.1=0.0678, wR.sub.2=0.1213 for all 3686 data.
[0151] Crystal packing: The co-crystals are sustained by hydrogen
bonded carboxamide-carboxylic heterodimers between the
carbamazepine moieties and the butyric acid moieties. The second
1.degree. amine hydrogen from each CBZ joins 2 heterodimers side by
side forming a tetramer.
[0152] Infrared Spectroscopy: (Nicolet Avatar 320 FTIR). 3486
cm.sup.-1, (N--H stretch, 1.degree. amine, CBZ); 3307 cm.sup.-1,
(C--H stretch, alkene); 1684 cm.sup.-1, (C.dbd.O); 1540 cm.sup.-1,
(C.dbd.C),
[0153] Melting Point: 63-64.degree. C. (MEL-TEMP). (carbamazepine
m.p.=191-192.degree. C., butyric acid m.p.=-94.degree. C.).
[0154] Thermogravimetric Analysis: (TA Instruments 2950
Hi-Resolution TGA). 16% weight loss starting at 54.degree., a 16%
weight loss starting at 134.degree. and a 49% weight loss starting
at 174.degree. followed by complete decomposition.
Example 16
Multi-Component Crystal of Carbamazepine:Carbamazepine/DMSO (1:1
Stoichiometry)
[0155] 25 mg (0.1058 mmol) carbamazepine was dissolved in
approximately 1.5 mL DMSO. Slow evaporation of the solvent yielded
colorless plates of a 1:1 carbamazepine/DMSO co-crystal, as shown
in FIG. 20B.
[0156] Crystal data: (Bruker SMART-APEX CCD Diffractometer)
C.sub.34H.sub.36H.sub.4O.sub.4S.sub.2, M=628.79, triclinic P-1;
a=7.3254(19), b=8.889(2), c=12.208(3) .ANG.,
.alpha.=94.840(5).degree., .beta.=94.926(5).degree.,
.gamma.=100.048(5).degree., V=775.8(3) .ANG..sup.3, T=200(2) K,
Z=2, .mu.(MO-K.alpha.)=0.216 mm.sup.-1, D.sub.c=1.320 Mg/m.sup.3,
.lamda.=0.71073 .ANG..sup.3, F(000)320,
2.theta..sub.max=28.3.degree.. 4648 reflections measured, 3390
unique (R.sub.int=0.0459). Final residuals for 209 parameters were
R.sub.1=0.0929, wR.sub.2=0.3043 for I>2.sigma.(I).
[0157] Crystal packing: The co-crystals are sustained by the
hydrogen bonded carboxamide homosynthon. The 1.degree. amines are
hydrogen bonded to the sulfoxide of the DMSO on each side of the
homosynthon. The crystal is stabilized by .pi.-.pi. interactions
from the tricyclic azepine ring system groups of the CBZ.
[0158] Infrared Spectroscopy: (Nicolet Avatar 320 FTIR). 3369
cm.sup.-1 (N--H stretch, 1.degree. amine, CBZ); 1665 cm.sup.-1
(C.dbd.O stretching); 1481cm.sup.-1 (C.dbd.C).
[0159] Differential Scanning Calorimetry; (TA Instruments 2920
DSC). 100.degree. C., 193.degree. C. (endotherms). m.p.=189.degree.
C. (MEL-TEMP). (carbamazepine m.p.=191-192.degree. C., DMSO
m.p.=18.45.degree. C.)
[0160] Thermogravimetric Analysis: (TA Instruments 2950
Hi-Resolution TGA). 26% weight loss starting at 102.degree., a 64%
weight loss starting at 212.degree. followed by complete
decomposition.
Example 17
Multi-Component Crystal of Carbamazepine: Carbamazepine/Formamide
(1:1 Stoichiometry)
[0161] 10 mg (0.0423 mmol) carbamazepine was dissolved in a mixture
of approximately 1 mL formamide/1 mL THF or 1 mL formamide/1 mL
methanol. Slow evaporation of the solvent mixture produced an
average yield of clear needles of a 1:1 carbamazepine/formamide
co-crystal, as shown in FIG. 21B.
[0162] Crystal data: (Broker SMART-APEX CCD Diffractometer).
C.sub.16H.sub.15N.sub.3O.sub.2, M=281.31, triclinic P-1;
a=5.1077(11), b=16.057(3), c=17.752(4) .ANG.,
.alpha.=73.711(3).degree., .beta.=89.350(3).degree.,
.gamma.=88.636(3).degree., V=1397.1(5) .ANG..sup.3, T=100.degree.
K, Z=4, .mu.(MO-K.alpha.)=0.091 D.sub.c=1.337 Mg/m.sup.3,
.lamda.=0.71073 .ANG..sup.3, F(000)592,
2.theta..sub.max=28.33.degree.. 11132 reflections measured, 6272
unique (R.sub.int=0.1916). Final residuals for 379 parameters were
R.sub.1=0.0766 and wR.sub.2=0.1633 for I>2.sigma.(I).
[0163] Crystal packing: The co-crystals are sustained by hydrogen
bonded carboxamide homodimers between two carbamazepine moieties
and carboxylic acid homodimers between two formamide moieties.
Infinite chains are formed by the homodimers linked side by side,
with every other set of CBZ molecules attached on the sides of the
chain but not bonded to form a dimer.
[0164] Infrared Spectroscopy: (Nicolet Avatar 320 FTIR). 3392
cm.sup.-1, (N--H stretch, 1.degree. amine, CBZ); 2875 cm.sup.-1,
(C--H stretch, alkene); 1653 cm.sup.-1, (C.dbd.O); 1590 cm.sup.-1,
(C.dbd.C).
[0165] Melting Point: 142-144.degree. C. (MEL-TEMP). (carbamazepine
m.p.=191-192.degree. C., formamide m.p.=-94.degree. C.).
[0166] Thermogravimetric Analysis: (TA Instruments 2950
Hi-Resolution TGA). 27% weight loss starting at 138.degree., a 67%
weight loss starting at 195.degree. followed by complete
decomposition.
Example 18
Multi-Component Crystal of Carbamazepine:Carbamazepine/formic acid
(1:1 stoichiometry)
[0167] 40 mg (0.1693 mmol) carbamazepine was dissolved in
approximately 2 mL formic acid. Slow evaporation of the solvent
yielded off-white starbursts of a 1:1 carbamazepine/formic acid
co-crystal, as shown in FIG. 22B.
[0168] Crystal data: (Bruker SMART-APEX CCD Diffractometer),
C.sub.16H.sub.14N.sub.2O.sub.3, M=282.29, monoclinic P21/c;
a=5.2031(9), b=14.741(2), c=17.882(3) .ANG., .alpha.=90.degree.,
.beta.=98.132(3).degree., .gamma.=90.degree., V=1357.7(4)
.ANG..sup.3, T=100 K, Z=4, .mu.(MO-K.alpha.)=0.097 mm.sup.-1,
D.sub.c=1.381 Mg/m.sup.3, .lamda.=0.71073 .ANG..sup.3, F(000)592,
2.theta..sub.max=28.3. 9402 reflections measured, 3191 unique
(R.sub.int=0.111). Final residuals for 190 parameters were
R.sub.1=0.0533 and wR.sub.2=0.1268 for I>2.sigma.(I).
[0169] Crystal packing: The co-crystals are sustained by hydrogen
bonded carboxylic acid-amine heterodimers arranged in
centrosymmetric tetramers.
[0170] Infrared Spectroscopy: (Nicolet Avatar 320 FTIR). 3439
cm.sup.-1, (1.degree. amine stretch, CBZ); 3026 cm.sup.-1 (C--H
stretch, CBZ); 1692 cm.sup.-1, (1.degree. amide, C.dbd.O
stretch).
[0171] Melting Point: 187.degree. C. (MEL-TEMP). (carbamazepine
m.p.=191-192.degree. C., formic acid m.p.=8.4.degree. C.).
[0172] Thermogravimetric Analysis: (TA Instruments 2950
Hi-Resolution TGA). 14.60% weight loss starting at 123.degree. and
a 68.91% weight loss starting at 196.degree. followed by complete
decomposition.
Example 19
Multi-Component Crystal of Carbamazepine:Carbamazepine/Trimesic
Acid (1:1 Stoichiometry)
[0173] 36 mg (0.1524 mmol) carbamazepine and 31 mg (0.1475 mmol)
trimesic acid were dissolved in a solvent mixture of approximately
2 mL methanol and 2 mL dichloromethane. Slow evaporation of the
solvent mixture yielded white starbursts of a 1:1
carbamazepine/trimesic acid co-crystal, as shown in FIG. 23B.
[0174] Crystal data: (Bruker SMART-APEX CCD Diffractometer),
C.sub.24H.sub.18N.sub.2O.sub.7, M=446.26, monoclinic C2/c;
a=32.5312(50), b=5.2697(8), c=24.1594(37) .ANG.,
.alpha.=90.degree., .beta.=98.191(3).degree., .gamma.=90.degree.,
V=4099.39(37) .ANG..sup.3, T=-173 K, Z=8, .mu.(MO-K.alpha.)=0.110
mm.sup.-1, D.sub.c=1.439 Mg/m.sup.3, .lamda.=0.71073 .ANG..sup.3,
F(000)1968, 2.theta..sub.max=26.43.degree.. 11581 reflections
measured, 4459 unique (R.sub.int=0.0611). Final residuals for 2777
parameters were R.sub.1=0.1563, wR.sub.2=0.1887 for
I>2.sigma.(I), and R.sub.1=0.1441, wR.sub.2=0.1204 for all 3601
data.
[0175] Crystal packing: The co-crystals are sustained by hydrogen
bonded carboxylic acid homodimers between carbamazepine and
trimesic acid moieties and hydrogen bonded carboxylic acid-amine
heterodimers between two trimesic acid moieties arranged in a
stacked ladder formation.
[0176] Infrared Spectroscopy: (Nicolet Avatar 320 FTIR). 3486
cm.sup.-1(N--H) stretch, 1.degree. amine, CBZ); 1688 cm.sup.-1
(C.dbd.O, 1.degree. amide stretch, CBZ); 1602 cm.sup.-1 (C.dbd.C,
CBZ).
[0177] Differential Scanning calorimetry: (TA Instruments 2.920
DSC). 273.degree. C. (endotherm). m.p.=NA, decomposes at
278.degree. C. (MEL-TEMP). (carbamazepine m.p.=191-192.degree. C.,
trimesic acid m.p.=380.degree. C.)
[0178] Thermogravimetric Analysis: (TA Instruments 2950
Hi-Resolution TGA). 62.83% weight loss starting at 253.degree. and
a 30.20% weight loss starting at 278.degree. followed by complete
decomposition.
[0179] X-ray powder diffraction: (Rigaku Miniflex Diffractometer
using CuK.alpha. (.lamda.=1.540562), 30 kV, 15 mA). The powder data
were collected over an angular range of 3 to 40 2 in continuous
scan mode using a step size of 0.02 2 and a scan speed of 2.0/min.
XRPD analysis experimental: 10.736, 12.087, 16,857, 24.857,
27,857.
[0180] All patents, patent applications, provisional applications,
and publications referred to or cited herein are incorporated by
reference in their entirety, including all figures and tables, to
the extent they are not inconsistent with the explicit teachings of
this specification,
[0181] It should be understood that the examples and embodiments
described herein are for illustrative purposes only and that
various modifications or changes in light thereof will be suggested
to persons skilled in the art and are to be included within the
spirit and purview of this application.
* * * * *